Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Accurate prognosis represents a critical component in oncology research, enabling personalized treatment planning and optimized health care resource use. Although existing prognostic models demonstrate promising performance on restricted data sets, they remain constrained by two limitations: modality-specific architectural designs and cancer type-specific training paradigms that hinder cross-domain generalization. To address these challenges, the Unified Multimodal Pan-Cancer Survival Network (UMPSNet) is introduced, which integrates histopathology images, genomic expression profiles, and four metadata categories through structured text templates. UMPSNet uses the optimal transport-based attention for multimodal feature alignment and a guided mixture of experts mechanism to address cancer-type distribution shifts. Comprehensive evaluation across 3523 whole slide images (n = 2831) spanning five The Cancer Genome Atlas cohorts demonstrated superior predictive performance (mean concordance index = 0.725), surpassing meticulously designed single-cancer models. Notably, in zero-shot transfer evaluation involving 392 pancreatic adenocarcinoma whole slide images (n = 66) from Peking University Third Hospital, UMPSNet achieved a concordance index of 0.652 without parameter fine-tuning, demonstrating generalization capacity for previously unseen malignancies. Additionally, UMPSNet identified prognostic gene signatures that consistently overlapped with clinically detected mutations (n = 92) while revealing novel gene candidates, validating its clinical relevance and providing complementary insights for precision oncology. The UMPSNet framework establishes a new paradigm for multimodal survival analysis by overcoming data heterogeneity and domain shift challenges, thereby providing a clinically adaptable tool for pan-cancer prognostic prediction.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2025.06.006DOI Listing

Publication Analysis

Top Keywords

survival analysis
8
slide images
8
umpsnet
5
single-cancer pan-cancer
4
pan-cancer prognosis
4
multimodal
4
prognosis multimodal
4
multimodal deep
4
deep learning
4
learning framework
4

Similar Publications

Resolve and regulate: Alum nanoplatform coordinating STING availability and agonist delivery for enhanced anti-tumor immunotherapy.

Biomaterials

September 2025

Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, PR China; University of Chinese Academy of Sciences, Beijing, 100049, PR China. Electronic address:

The stimulator of interferon genes (STING) pathway represents a promising target in cancer immunotherapy. However, the clinical translation of cyclic dinucleotide (CDN)-based STING agonists remains hindered by insufficient formation of functional CDN-STING complexes. This critical bottleneck arises from two interdependent barriers: inefficient cytosolic CDN delivery and tumor-specific STING silencing via DNA methyltransferase-mediated promoter hypermethylation.

View Article and Find Full Text PDF

Gene dysregulation impairs placental angiogenesis in allogeneic pig pregnancies.

Anim Reprod Sci

September 2025

Department of Biomedical & Clinical Sciences (BKV), BKH/Obstetrics & Gynecology, Faculty of Medicine and Health Sciences, Linköping University, Linköping SE-58185, Sweden.

Embryo transfer (ET) is a valuable reproductive technology in pigs, albeit its efficiency remains significantly lower than that of natural mating or artificial insemination (AI), owing to high embryonic death rates. Critical for embryo survival and pregnancy success is the placenta, which supports conceptus development through nutrient exchange, hormone production, and immune modulation. Alterations in placental development and function may therefore underlie the reduced efficiency of ET.

View Article and Find Full Text PDF

Background: Sarcomas are rare cancer with a heterogeneous group of tumors. They affect both genders across all age groups and present significant heterogeneity, with more than 70 histological subtypes. Despite tailored treatments, the high metastatic potential of sarcomas remains a major factor in poor patient survival, as metastasis is often the leading cause of death.

View Article and Find Full Text PDF

Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.

View Article and Find Full Text PDF

Purpose: In Armenia, a lower-middle-income country, cancer causes 21% of all deaths, with over half of cases diagnosed at advanced stages. Without universal health insurance, patients rely on out-of-pocket payments or black-market channels for costly immunotherapies, underscoring the need for real-world data to inform equitable policy reforms.

Methods: We conducted a multicenter, retrospective cohort study of patients who received at least one dose of an immune checkpoint inhibitor (ICI) between January 2017 and December 2023 across six Armenian oncology centers.

View Article and Find Full Text PDF